A Chinese drugmaker most American readers have never heard of just added two of biotech's best-known names to its contact list.
According to Endpoints News, Haisco Pharmaceutical, a China-based drugmaker, has struck an alliance with ARCH Venture Partners — the firm co-founded by Bob Nelsen, one of the most prominent venture investors in life sciences — and Population Health Partners. Endpoints describes the pair as "two dominant names in biotech."
The outlet reports that the tie-up is not a one-off. Haisco has been on what Endpoints calls a "dealmaking tear this summer," making this the latest in a run of partnerships rather than a first step abroad.
Endpoints frames the deal as part of a broader "China blitz" — a wave of Western biotech money and expertise flowing toward Chinese drug developers. The specific terms of the Haisco arrangement, including which drug candidates are involved and how much money is changing hands, are not detailed in the material available here.
Why it matters: for years, the flow of pharmaceutical innovation ran mostly from the US and Europe outward, but when marquee American investors like ARCH start writing checks into Chinese pipelines, it signals that the industry increasingly sees China as a source of drugs worth buying rather than just a market to sell into — a shift with consequences for where the next generation of medicines gets discovered, and for the policymakers now scrutinizing those cross-border ties.